4SC has announced an updated development programme, to be funded by an equity fund-raising, which we expect in 2017. The proceeds from this will be used to accelerate development of 4SC’s leading drug candidates. This will include continuing to progress resminostat in CTCL (initiated at end 2016), a subsequent filing of a marketing authorisation application in Europe (2019) and progression of resminostat into a further pivotal study in HCC (2018). 4SC also expects a pivotal study in 4SC
17 May 2017
Intention to raise equity to progress development
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Intention to raise equity to progress development
4SC AG (VSC:FRA) | 0 0 4.2% | Mkt Cap: 249.2m
- Published:
17 May 2017 -
Author:
Dr Linda Pomeroy -
Pages:
3
4SC has announced an updated development programme, to be funded by an equity fund-raising, which we expect in 2017. The proceeds from this will be used to accelerate development of 4SC’s leading drug candidates. This will include continuing to progress resminostat in CTCL (initiated at end 2016), a subsequent filing of a marketing authorisation application in Europe (2019) and progression of resminostat into a further pivotal study in HCC (2018). 4SC also expects a pivotal study in 4SC